Emtricitabine
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Emtricitabine: From HIV Infection to Feline Acquired Immunodeficiency Syndrome
One-Sentence Summary
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) used as a cornerstone component of combination antiretroviral therapy (cART) for HIV-1 infection in humans, included in widely-used formulations such as Truvada and Descovy. The TxGNN model predicts it may be effective for Feline Acquired Immunodeficiency Syndrome (FIV infection in cats), with 4 clinical trials (indirect, all in human HIV-1) and 1 direct experimental publication in FIV-infected cats currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV-1 Infection (human; inferred from clinical trial context — no India market approval on record) |
| Predicted New Indication | Feline Acquired Immunodeficiency Syndrome |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, Emtricitabine (FTC) is a fluorinated cytidine analogue. After intracellular phosphorylation to its active triphosphate form (FTC-TP), it competes with natural deoxycytidine triphosphate for incorporation into the nascent viral DNA strand, acting as an obligate chain terminator of reverse transcriptase (RT) — thereby blocking viral RNA-to-DNA conversion. This mechanism is definitively established for HIV-1 in humans.
Feline Immunodeficiency Virus (FIV) belongs to the Lentivirus genus, the same viral family as HIV-1 and HIV-2. FIV and HIV-1 share structural homology in their reverse transcriptase enzymes, which is the mechanistic basis for this repurposing prediction. Importantly, a 2023 experimental study (PMID 37112803) directly tested a cART regimen including Emtricitabine (40 mg/kg) alongside Dolutegravir and Tenofovir in FIV-infected domestic cats, providing the first in-species pharmacokinetic and immunophenotypic data. Additionally, the M184V resistance mutation — through which FTC resistance emerges in HIV — has been documented in SIV primate models treated with emtricitabine (PMID 12021341), demonstrating cross-lentiviral conservation of the drug-target interaction mechanism.
However, several critical unknowns limit immediate translation. Feline-specific pharmacokinetics (oral bioavailability, tissue distribution, hepatic metabolism) differ substantially from humans; cats are known to have limited glucuronidation capacity. The sequence divergence between FIV RT and HIV-1 RT may affect binding affinity and chain-termination efficiency. These gaps require dedicated feline pharmacology studies before any clinical recommendation can be made.
Clinical Trial Evidence
Important context: No registered clinical trials directly study Emtricitabine in feline AIDS. The four trials below evaluated Emtricitabine as a backbone component of human HIV-1 combination regimens. They are listed here as indirect mechanistic support, confirming the drug’s antiviral activity and safety profile via its RT-inhibiting mechanism — the same mechanism proposed for FIV.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01227824 | Phase 3 | Completed | 828 | Non-inferiority of dolutegravir vs raltegravir, both combined with TDF/FTC or ABC/3TC, over 96 weeks in ART-naïve HIV-1 adults; establishes FTC-containing backbone efficacy at scale |
| NCT01263015 | Phase 3 | Completed | 844 | Dolutegravir + ABC/3TC vs Efavirenz/Emtricitabine/TDF (Atripla) over 96 weeks in ART-naïve HIV-1 adults; long-term safety and resistance data for FTC confirmed |
| NCT00951015 | Phase 2 | Completed | 208 | Dose-selection study for dolutegravir administered with TDF/FTC or ABC/3TC; provides safety and tolerability data for FTC as part of combination regimens |
| NCT02770508 | Phase 4 | Completed | 145 | Boosted darunavir + lamivudine vs boosted darunavir + TDF/FTC in ART-naïve HIV-1 patients; comparative safety profile of FTC-containing dual-NRTI backbone |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37112803 | 2023 | Experimental Animal Study (FIV cat model) | Viruses | cART (Dolutegravir 2.5 mg/kg + Tenofovir 20 mg/kg + Emtricitabine 40 mg/kg) administered to FIV-infected domestic cats; evaluated pharmacokinetics and immunophenotype — the only direct in-species study available for this indication |
India Market Information
Emtricitabine currently has no approved or registered products in India as of the data cutoff (April 2026). No license records are available for review.
Safety Considerations
Drug Interactions (20 interactions identified; source: DDInter):
| Severity | Interacting Drugs |
|---|---|
| Major | Leflunomide, Teriflunomide |
| Moderate | Orlistat, Naltrexone, Cobicistat, Asparaginase Escherichia coli, Interferon beta-1a, Interferon beta-1b, Brentuximab vedotin, Cabozantinib, Cladribine, Clofarabine, Epirubicin, Idelalisib, Methotrexate, Pegaspargase, Peginterferon beta-1a, Tioguanine, Trabectedin |
| Minor | Eribulin |
For key warnings and contraindications, please refer to the full package insert, as this information was not captured in the current evidence pack.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for Emtricitabine in feline acquired immunodeficiency syndrome remains at L4 (a single experimental cat study published in 2023), with no dedicated clinical trials and no regulatory precedent in veterinary medicine for this species-indication pair. While the mechanistic case is scientifically coherent — FIV shares lentiviral RT homology with HIV — species-specific pharmacology has not been adequately characterized to support advancement.
Note on secondary predictions: The second-ranked TxGNN prediction — Simian Immunodeficiency Virus (SIV) infection (score 99.92%, L3 evidence, recommendation: Proceed with Guardrails) — carries a meaningfully stronger evidence base, with 20 macaque studies (SHIV/SIV challenge models) demonstrating Emtricitabine’s efficacy in pre-exposure prophylaxis and treatment. If the research goal is lentiviral disease modeling or primate translational research, SIV infection represents a more immediately actionable avenue.
To proceed with feline AIDS indication, the following is needed:
- Species-specific PK/PD study in cats: oral bioavailability, plasma half-life, renal and hepatic clearance, target tissue (lymphoid) penetration
- In vitro FIV RT inhibition assay with FTC-TP to confirm susceptibility and determine IC₅₀ vs HIV-1 RT
- FIV challenge model study with defined virological endpoints (plasma viral load, CD4⁺ T-cell counts, clinical scoring)
- Feline safety and tolerability study including renal, hepatic, and haematological monitoring (cats are at particular risk with certain NRTIs)
- Full mechanism of action documentation via DrugBank API or package insert review
- Regulatory pathway scoping for veterinary drug approval in India (CDSCO veterinary division) or international reference (e.g., EMA veterinary procedures)
This report is for research reference only and does not constitute medical or veterinary advice. Drug repurposing candidates require clinical validation before application. Data cutoff: 2026-04-04.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.